ClinicalTrials.gg
RecruitingNCT04727593MINDGAPUpdated Sep 5, 2023

The Modulatory Role of Internet MBCT on Extracellular Vesicles and Distress in Cancer Patients - Study Protocol

An interventional study of Mindfulness Based Cognitive Therapy (MBCT) and Treatment as Usual in Cancer, sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto. Recruiting at 1 site in Portugal. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-09-05.

Sponsored by Instituto Portugues de Oncologia, Francisco Gentil, Porto · Not applicable, Interventional, and Supportive care

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2024, 2 years 8 months ago, but the record still lists the study as recruiting.
  • Started Sep 2021; still recruiting 5 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
111
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Mindfulness-based interventions (MBIs), such as mindfulness-based stress reduction (MBSR), mindfulness-based cognitive therapy (MBCT), mindfulness-based cancer recovery (MBCR), have been showing promising results in different health-related and psychosocial outcomes in the context of cancer. More recently, the possibility of delivering MBIs using technological tools and resources, such as internet and applications, has been receiving much attention, also accompanied by promising findings. However, few randomized controlled studies have been conducted and published to date. Moreover, few studies have addressed the long-term stability and trajectory of gains across time. Also, even though prior evidence had suggested that face-to-face MBIs might modulate several biological markers (e.g., pro-inflammatory gene expression and inflammatory signaling; telomere length), as far as we know, no previous study addressed the impact of online MBIs on biological indices, especially on extracellular vesicles (EVs).

As primary objective, this study aims to investigate the effects of an internet-based MBCT intervention (vs. Treatment as Usual - TAU) on EVs (objective measure), as well as on psychological distress (subjective measure), considering a sample of distressed people with history of breast, prostate, and colorectal cancer.

As secondary objective, this study aims to investigate the effects of this same intervention on psychosocial outcomes, including quality of life, fear of cancer recurrence, emotion suppression, mindfulness, sleep quality, posttraumatic growth, health-related behaviours (physical activity; smoking habits), and perceived social support. The biological secondary outcomes studied will be: inflammatory response genes interleukins (ILs, IL-1, IL-6, IL-8, IL-10), interferon gamma (IFN-γ), tumour necrosis factor (TNF), and c-reactive protein (CRP); telomerase activity; antigens related to cancer (cancer antigen - CA 15-3; prostate-specific antigen - PSA; carcinoembryonic antigen - CEA); other health-related markers (adrenocorticotropic hormone - ACTH; erythrocytes number; hemoglobin glycosylated).

02

Conditions studied

  • Cancer

Keywords

  • Cancer
  • Internet
  • Extracellular vesicles
  • Distress
  • Mindfulness
  • Mindfulness Based Cognitive Therapy
  • Anxiety
  • Depression
  • Biomarkers
  • eHealth
  • Telehealth
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 111 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Instituto Portugues de Oncologia, Francisco Gentil, Porto is the lead sponsor of 8 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of breast, prostate, or colorectal cancer;
  • Cancer stage I - III;
  • Primary cancer treatments completed between 3 months and 5 years (participants with ongoing hormonal therapies will be included);
  • Age between 18 and 65 years;
  • Experiencing significant distress on the Distress Thermometer (DT ≥ 4)
  • Willingness to accept randomization to one of the two study conditions and to attend the study for its duration;
  • Ability to speak, read, and write in Portuguese and literacy to complete autonomously the self-report measures;
  • Sufficient digital literacy with access to a device (e.g., smartphone; tablet; computer) with camera, microphone, and internet.

Exclusion criteria

Exclusion Criteria:

  • Concurrent diagnosis of severe psychiatric condition(s) (e.g., psychosis; substance abuse; bipolar disorder; suicidal ideation);
  • Concurrent diagnosis of disorder;
  • Current use of antipsychotics;
  • Current use of anti-inflammatory medication (corticotherapy);
  • Undergoing trastuzumab therapy;
  • Participation in a structured mindfulness program (e.g., MBCT; MBSR; Mindfulness-Based Cancer Recovery - MBCR) program in the past five years;
  • Currently attending psychological consultation;
  • Being pregnant or breastfeeding.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
111 participants (estimated)

Study arms

  • Experimental
    Mindfulness Based Cognitive Therapy (MBCT)

    Group intervention on Mindfulness-Based Cognitive Therapy classic program plus 4 monthly consolidation sessions of 90 minutes each.

    Behavioral: Mindfulness Based Cognitive Therapy (MBCT)

  • Other
    Treatment as Usual (TAU)

    TAU will be the control condition.

    Other: Treatment as Usual

Interventions

  • BehavioralMindfulness Based Cognitive Therapy (MBCT)

    Experimental group: MBCT is program developed by Zindel Segal, Mark Williams, and John Teasdale , based on Jon Kabat-Zinn's Mindfulness-based Stress Reduction (MBSR) program. Participants learn to acknowledge their unhelpful thoughts and feelings, allowing the mind to move from an automatic and spiraling thought pattern to a more conscious emotional processing. Mindfulness practices include breath awareness, sitting and walking meditations, and mindful yoga. In this study, the following MBCT structure will be followed: group setting of 12 participants (maximum); 8 online weekly meetings of 2 hours via a videoconference platform (e.g., Cisco Webex), each one mediated by a trained mindfulness instructor(s); daily home practice of the learned skills; 2 hours of retreat after the fifth week; 6 months of home practice; 4 monthly consolidation sessions of 90 minutes each.

  • OtherTreatment as Usual

    In this case, participants will follow the usual institutional intervention protocol for medical follow-up and identification, referral, and intervention for people with significant distress difficulties. Regarding pharmacological intervention, medication intake will be monitored during the study and changes will be registered. The engagement in non-pharmacological interventions such as psychological and psychosocial interventions will also be monitored.

06

What researchers measure

Primary outcomes

  1. Change on Extracellular Vesicles

    Isolated by ultracentrifugation with sucrose cushion. The collected EVs will be quantified by Nanoparticle tracking analysis (Nanosight Ltd.), and data will be measured in particles per milliliter (mL).

    Time frame: T1 - before intervention; 8 weeks after T1; 24 weeks after T1

  2. Change on Distress

    Measured with Depression Anxiety Stress Scales-21 - DASS-21, a self-report and public domain questionnaire that evaluates negative affective states. It is composed of 21 items, 7 focused on depression, 7 on anxiety, and 7 on stress. Each item is rated on a 4-point Likert-type scale, wherein in 0 represents "did not apply to me at all" and 3 represents "applied to me very much or most of the time". The score for each subscale ranges between 0 and 21. In the current study, a total score will be computed by summing all items, with higher scores being indicative of higher self-reported psychological distress.

    Time frame: T1- before intervention; T2 - 4 weeks after baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

Secondary outcomes

  1. Change on Cancer antigen 15-3 (CA 15-3)

    Using an immunoassay analyser (units/mL).

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  2. Change on Prostate-specific antigen (PSA)

    Using an immunoassay analyser (ng/mL).

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  3. Change on Carcinoembryonic Antigen (CEA).

    Using an immunoassay analyser (ng/mL).

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  4. Change on Adrenocorticotropic Hormone (ACTH).

    Using an immunoassay analyser (pg/mL).

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  5. Transcript inflammatory response genes (Interleukins, ILs, IL-1, IL-6, IL-8, IL-10, IFNγ and TNF).

    Assessed by quantitative RT-PCR (TaqMan™ Gene Expression Assays).

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  6. Change on Analytic biomarkers (Erythrocyte number).

    This indicator assesses erythrocytes number (million/mm3) from blood samples (Sysmex XN).

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  7. Change on Analytic biomarkers (PCR number).

    This indicator assesses PCR (mg/L) from blood samples.

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  8. Change on Analytic biomarkers (telomerase activity).

    This indicator assesses telomerase activity (units) from blood samples.

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  9. Change on Analytic biomarkers (hemoglobin glycosylated).

    This indicator assesses High Performance Liquid Chromatography - HPLC, (mmol/mol) from blood samples.

    Time frame: T1- before intervention; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline

  10. Change on Global distress

    Measured with Clinical Outcome Routine Evaluation - Outcome Measure, (CORE-OM) , a self-report measure of global distress (GD), comprising 34 items and four domains: subjective well-being, commonly experienced problems or symptoms, social/life functioning, and risk to self and others. The measure is scored on a 5-point scale ranging from 0 ('not at all') to 4 ('all the time'). The measure is suitable for use across a wide range of settings, it has been validated in different adult population with mental health problems, and it is sensitive to change.

    Time frame: T0 - Screening; T2 - 4 weeks after baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  11. Change on quality of life

    Measured by World Health Organization Quality of Life - Bref - WHOQOL-Bref, a questionnaire suitable for epidemiological and clinical trials, which assesses quality of life as proposed by WHO. It is composed of 26 items distributed in one general facet and four domains (physical health, psychological, social relationships, and environment). Each item is rated on a 5-point Likert-type scale with higher scores being indicative of better self-reported quality of life (scoring procedures are available here: https://www.who.int/mental_health/media/en/76.pdf).

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  12. Change on fear of cancer recurrence

    Measured by a 7-item Fear of Cancer Recurrence - FCR-7 (PT version not yet available), a 7-item scale assessing fear of cancer recurrence in a 5-point Likert scale ranging from 1 (not at all) to 5 (all the time). It had demonstrated good psychometric properties. We will translate, adapt and validate this measure, following the usual procedures to adapt psychological measures.

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  13. Change on satisfaction perceived social support

    Satisfaction with Social Support Scale - SSSS, a 15-item scale assessing social support satisfaction discriminating four dimensions: satisfaction with friends/friendships, intimacy, satisfaction with family and social activities.

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  14. Change on emotional suppression

    Emotion Regulation Questionnaire - ERQ) , - Only the subscale of emotion suppression composed of 4-items will be used. The items are rated in 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree).

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  15. Change on mindfulness abilities

    Measured by Mindfulness Five Facet Mindfulness Questionnaire - FFMQ, a 39 items questionnaire that assess mindfulness and self-awareness states in everyday life, which are organized in five different facets/subscales: observing, describing, acting with awareness, nonreactivity to inner experience, and nonjudging of inner experience. Each item is rated on a 5-point Likert-type scale ranging from 1 (never or very rarely true) and 5 (very often or always true).

    Time frame: T1 Baseline; T2 - 4 weeks after baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  16. Change Interview

    This interview assesses the psychotherapeutic changes perceived by participants after psychological intervention. The interview questions explore the changes that a person has noticed since therapy began, what the person attributes these changes to, and helpful and unhelpful aspects of therapy, in a qualitative way.

    Time frame: T3 - 8 weeks after baseline

  17. Change on smoking dependency

    Measured with Fageström Test for Nicotine Dependence - FTND. This instrument assesses nicotine dependency with 6 items (rated from 0 to 2 or 3). The total score range is 1-10, with higher values meaning higher nicotine dependency.

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  18. Change on physical activity

    Measured with International Physical Activity Questionnaire - Short Form - IPAQ-SF. This instrument assesses physical activity in 7 items, with higher scores meaning higher level of physical activity.

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  19. Change on sleep quality

    Measured with Basic Scale on Insomnia complaints and Quality of Sleep - BaSIQS - This is a self-report measure that focus on evaluating sleep quality, as well as problems to fall asleep and maintain sleep. It encompasses 7 items rated in a 5-point Likert-type and the total score ranges between 0 and 28, with highest values indicating poor sleep quality. Satisfactory psychometric properties were reported in the original study with Portuguese higher education students, but also on community and clinical samples

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

  20. Change on posttraumatic growth

    Measured with Posttraumatic Growth Inventory - PTGI, which is a self-report questionnaire that evaluates positive psychological change in people experiencing traumatic events. It includes 21 items and each item is rated on a 6-point Likert-type scale ranging from 0 ("I did not experience this change as a result of my crisis") to 5 ("I experienced this change to a very great degree as a result of my crisis"). Total score ranges between 0 and 105, with higher values being indicative of a greater degree of posttraumatic growth.

    Time frame: T1 - Baseline; T3 - 8 weeks after baseline; T4 - 24 weeks after baseline; T5 - 52 weeks after baseline

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Pereira DR, Silva ER, Carvalho-Maia C, Monteiro-Reis S, Lourenco C, Calisto R, Teixeira RJ, Carlson LE, Bart G, Vainio SJ, Sales MGF, Jeronimo C, Henrique R. The modulatory role of internet-supported mindfulness-based cognitive therapy on extracellular vesicles and psychological distress in people who have had cancer: a protocol for a two-armed randomized controlled study. Trials. 2022 Feb 5;23(1):118. doi: 10.1186/s13063-022-06045-x. PubMed 35123569 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2021 (actual). Primary completion is estimated for Mar 2024, 29 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 29 months is close to that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 18, 2021
First posted
Jan 27, 2021
StartActual
Sep 3, 2021
Primary completionEst.
Mar 1, 2024
CompletionEst.
Mar 31, 2024
Last update
Sep 5, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 5, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04727593
Lead sponsor
Instituto Portugues de Oncologia, Francisco Gentil, Porto
Collaborators
European Commission, University of Coimbra, VTT Technical Research Centre, Finland, University of Oulu, Linnaeus University
Responsible party
Sponsor
First posted
Jan 27, 2021
Start date
Sep 3, 2021
Primary completion
Mar 1, 2024 (estimated)
Completion
Mar 31, 2024 (estimated)
Last update
Sep 5, 2023

Study contacts

Eunice Silva, PhD
Contact
esilva@ipoporto.min-saude.pt
00351 961761035
Carmen Jerónimo, PhD
Contact
carmenjeronimo@ipoporto.min-saude.pt
00351 225084000 ext. 1952
Rui Henrique, PhD
study director · Institute of Oncology of Porto, Portugal
Carmen Jerónimo, PhD
study director · Institute of Oncology of Porto, Portugal
Eunice Silva, PhD
study director · Institute of Oncology of Porto, Portugal

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion